 The FDA approves a new Alzheimer's treatment from Eli Lilly, CBS's Alexander Tinn. It looks to be effective at slowing the decline of patients at early stages of the disease after as little as six months of infusions from the drug. Eli Lilly says the treatment, which they have branded as Casundla, has a list price that adds up to some $32,000 if it is taken for a year.